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Abstract
Premature rupture of membranes (pPROM) affects about 4% of pregnancies and remains the 
main cause of preterm delivery (PTD). We currently lack a method for screening patients at 
high risk of pPROM as well as causal treatment for this yet not fully understood pathology of 
pregnancy. Promising, potential markers are proteins from a family of lectins – galectins. To 
date, 13 subtypes have been identified in humans. Particular galectins inhibit the mother's 
immune response to the fetus, thus enabling the maintenance of pregnancy and delivering at 
term. So far the role of some galectins has been proven in relation to early pregnancy 
complications, hypertension and preeclampsia, fetal growth disturbances (including fetuses 
small for gestational age, fetal growth restriction and macrosomia) and even in physiological 
processes which occur during healthy pregnancy. In reference to pPROM galectins seem to be
linked to pathomechanisms leading to weakening of the structure of membranes and in result 
their rupture. Examination of galectins appears to be crucial for understanding certain 
pathologies of pregnancy and gives hope for the effective identification of risk groups and 
future causal treatment. 
Introduction
Preterm premature rupture of fetal membranes (pPROM) is defined as a rupture of 
membranes before the end of 37th gestational week. It is estimated that this problem affects 
about 4% of pregnancies and is responsible for almost half of preterm deliveries (PTD) (1). 
Despite great advances in perinatal care in recent decades, the number of premature births 
caused by pPROM has been constantly increasing (2). We currently have numerous methods 
to facilitate the diagnosis (eg rapid tests that allow detection of IGFBP-1 or PAMG-1 from a 
vaginal swab sample, tests for vaginal pH), but we still do not have an effective tool to 
identify pPROM likelihood markers. Several risk factors have been recognized, including: 
bacterial or fungal infection in the reproductive tract at each stage of pregnancy, multiple 
pregnancy, polyhydramnion, vaginal bleeding in the first trimester, and socioeconomic factors
(including mainly cigarette smoking) (3), however, the exact pathophysiological mechanisms 
are not yet discovered. The currently prevailing view is that pPROM is a complication caused 
by the disease of the membranes themselves, in which the key role is played by oxidative 
stress (4), leading first to the weakening of the membrane structure and then to their rupture. 
Therefore, it is believed that the inflammatory process is secondary to pPROM, because due 
to the microdamages that occur, the membranes of the fetus become the gateway to potential 
infection (5). The putative markers which may effectively screen patients at high risk for 
pPROM are galectins.
Galectins are a group of proteins from a family of lectins, characterized by the ability 
to bind B-galactosides due to the presence of a sugar recognition domain - CRD 
(carbohydrate recognition domain) in their structure (6). To date, 13 subtypes have been 
identified in humans (7). They differ in structure and functions - from migration, through cell 
growth and differentiation, tolerance and immune response (8), to directing a cell to apoptosis
(9). Galectins are a subject of research in many fields of medicine, especially oncology and 
cardiology. Also in obstetrics, there are reports of their key role in, for example, the regulation
of trophoblast development, migration and invasion as well as placental angiogenesis (10). 
They are also responsible for signaling to direct cells of the fetal membranes to apoptosis in 
case of rupture of membranes (11). Therefore, galectins are accountable for the proper course 
of pregnancy. In relation to clinical trials in obstetrics and gynecology, their most interesting 
role seems to be the modulation of the immune response. Some galectins inhibit the mother's 
immune response to the fetus, thus enabling the maintenance of pregnancy and delivering at 
term (12). That is why their in-depth examination and learning mechanisms of action appears 
to be crucial for understanding some pathologies of pregnancy and gives hope for the 
effective identification of risk groups and future causal treatment.
Galectins in obstetrics
In the present light, pregnancy is an allogeneic transplant that leads to mild chronic 
inflammation in normal pregnancy (13,14). The expression of individual galectins was 
described in, inter alia, the placenta, fetal membranes, as well as in maternal blood, and they 
appear to be involved in the process of fetal tolerance by the mother, including regulation of 
the inflammatory response associated with pregnancy (7,15). 
Early pregnancy
Increased expression of individual galectins can be noticed at the earliest stages of 
pregnancy. The expression of galectin -1, -3 and -9 has already been described in relation to 
embryogenesis (9), and together with galectin-15 they also play an important role in the 
implantation process, enabling adhesion of the blastocyst to the uterine epithelium (16). 
Galectin expression affects not only trophoblast but also maternal immune cells. Galectin-1, 
inter alia, inhibits the proliferation of T-lymphocytes, leads to the apoptotic pathway of 
activated CD8 +, Th1 and Th17 cells, and inactivates pro-inflammatory cytokines (17,18). It 
also plays an important role in the apoptosis of activated T-cells present in the decidua (19), 
thus contributing to the maintenance of maternal tolerance to the fetus (15,19)
A study on a mouse model showed that the mice exposed to stress had lower 
expression of decidual galectin-1, which resulted in more frequent loss of pregnancy. 
Interestingly, this effect was reversible after exogenous administration of recombinant 
galectin-1, which may in the future be associated with the possibility of a potential causal 
treatment preventing early pregnancy loss (15).
Galectin-1 is also involved in the process of trophoblast invasion and placental 
angiogenesis. It stimulates the production of proangiogenic factors, thus ensuring the correct 
placental synthesis (20).
Galectin-9 creates an immunologically friendly environment for implantation thanks 
to its role in inducing the transformation of peripheral NK cells (natural killer) into uNK 
(uterine natural killer). A decreased number of uNK cells has been found in the case of 
miscarriage in the early stages of pregnancy, which suggests an important role of galectin-9 in
the maintenance of pregnancy (21).
The role of other galectins, including in particular galectin-3, -8, -13, -14, -15, -16 and 
-17, also seems to be important in the processes occurring in early pregnancy. However, they 
are less known but still of interest to both molecular biologists and clinicians.
Hypertension and preeclampsia
Preeclampsia is the most studied complication of pregnancy in terms of changes in the 
expression and concentration of galectins in several body fluids. It is also one of the most 
serious complication which affects approximately 7% of pregnancies and is associated with 
many aftermaths, including the risk of death for both the mother and the fetus (22). 
Overexpression of galectin-1 and -3 and decreased -13 were found in decidua and trophoblast 
cells both in patients with mild and severe preeclampsia and in HELLP (hemolysis, elevated 
liver enzymes, low platelet count) syndrome (23), which is related to abnormal trophoblast 
invasion leading to those complications (24). Interestingly, the abovementioned deviations 
from the norm already occur in the early stages of pregnancy, which will develop 
preeclampsia in the later weeks (25). In the peripheral blood of a mother with developing 
preeclampsia, a decreased amount of galectin-1 and -13 can be observed, which may serve as 
a marker of early preeclampsia in the future (26).
Fetal growth disturbances
Recent studies on the relationship of galectins with fetuses too small for gestational 
age (SGA) suggest that the smaller the child is compared to gestational age, the higher the 
concentration of galectin-3 in the umbilical cord blood, which may suggest a pivotal role of 
inflammation in this pathology. Similarly, in case of intrauterine growth restriction (IUGR), 
elevated concentrations of this galectin in the umbilical cord blood were found. This likely 
reflects the inflammatory response caused by chronic fetal hypoxia (27). On the other hand, 
Hutter et al. proved that in the placenta of IUGR-complicated fetuses there is a sex-dependent,
statistically significant overexpression of some galectins (galectin 4, 8 and 9 in male and 9 
and 12 in female) compared to placenta of fetuses with normal birth weight (28). The same 
research group in another study confirmed the association of reduced galectin-3 expression in 
fetal placenta with IUGR, regardless of fetal gender (29). A parallel study by Boutsikou et al. 
showed a correlation between the concentration of galectin-1 and galectin-3 in the blood 
plasma of multiparous women with fetuses with both macrosomia and IUGR (30).
Physiological delivery at term
The role of galectins has been investigated not only in the context of pathological 
pregnancy, but also in the physiological processes leading to childbirth. Delivery at term in a 
healthy woman is associated with local pro-inflammatory changes that initiate the opening 
and shortening of the cervix and contractions of the uterine muscle (31,32). During induction 
of labor with oxytocin, an increased concentration of galectin-7 is observed, while a decreased
expression of galectin-9 is noted at the site of rupture of fetal membranes (31). Moreover, the 
expression of galectin-1 is the highest in placenta in term pregnancies compared to its earlier 
stages. Galectin-1 is a placenta-specific protein, achieving about 28 times greater expression 
in the placenta compared to other body tissues (11).
Galectins in premature rupture of membranes
Premature rupture of the membranes is responsible for almost half of the preterm 
deliveries (1). It is also one of the few pathologies of pregnancy where the exact 
pathophysiological mechanism is unknown. We do not have specific methods of prevention of
pPROM and, consequently, causal treatment. It is nowadays believed that research regarding 
expression and concentration of galectins in different tissues and body fluids may hopefully 
answer at least some questions concerning pPROM. The expression of galectin-1, -7, -9, -13, 
-14, -16 and -17 is found in the fetal membranes themselves, but their exact functions and 
regulation mechanisms in this structure are unknown (7,33).
It is assumed that there is a relationship between galectins and premature rupture of 
membranes, which is associated in up to 75% with bacterial infection of the membranes 
and/or amniotic fluid (34). Galectin-1 is the most studied galectin in this pathology. It has 
been identified in all types of cells that build fetal membranes, including amniotic epithelial 
cells, chorionic trophoblast or chorio-vascular mesenchymal cells. Previous studies suggest 
that in the course of pPROM without membrane infection, its mRNA expression in fetal 
membranes is comparable to that observed in healthy pregnant women, while it increases in 
the case of pPROM with histopathologically confirmed inflammation of the membranes. 
Overexpression of galectin-1 in fetal membranes might be linked to weakening of their 
structure, increased susceptibility to infections and ultimately their rupture. Moreover, it is 
believed that galectin-1 serves as an active barrier protecting the fetus against bacterial 
infection and that it facilitates phagocytosis of excessively produced maternal neutrophils
(33).
Recent studies also suggest a role of galectin-3 in pPROM. It is a pro-inflammatory 
molecule which, similar to galectin-1, regulates the immune response. Its mechanism of 
action is inhibition of apoptosis of macrophages and monocytes. It also is their 
chemoattractant. However, the relationship between pPROM and galectin-3 concentration 
was proven only in the case of histopathologically confirmed inflammation of the membranes,
where the expression of galectin-3 was statistically significantly increased in the cytoplasm of
cells building fetal membranes (35). It is worth mentioning that due to their strong 
immunosuppressive properties, fetal membranes are used in ophthalmology to treat corneal 
injuries and in the transplantation of skin fragments, where they support the healing process 
and reduce the risk of transplant rejection. The galectins (mainly 1 and 3) are most likely 
responsible for the mentioned immunosuppressive effects (36).
New hope was provided by recent reports on confirmed differences in maternal 
galectin-1 and -3 concentrations in mother’s blood in pPROM patients compared to healthy 
pregnant women. Kaya et al. indicate that the above-mentioned galectins occur in statistically 
significantly higher concentrations in the serum of pregnant women with pPROM compared 
to healthy patients, regardless of the inflammation of the membranes or other inflammatory 
factors (37).
In the context of rupture of membranes, there are also references to galectin-9, whose 
expression in the chorion is reduced at the site of weakening of the membrane structure, 
which consequently leads to their rupture (31).
Summary
Galectins are ubiquitous proteins with multidirectional regulatory functions. Their 
expression is crucial both for the processes related to early pregnancy and for pathologies that 
appear along with its advancement. Research on the role of galectins in the pathophysiology 
of pregnancy is still at an early stage and requires further in-depth analysis. However, 
preliminary results suggest that some of them are promising candidates as potential markers 
of pre-eclampsia, SGA and IUGR, and may also be used as a causal treatment for recurrent 
and threatening miscarriages in the future. Galectins, in particular galectin 1, 3 and 9, may be 
a factor causing a cascade of unfavorable pathophysiological reactions leading to pPROM. 
They are also a promising object of research towards the discovery of markers allowing to 
distinguish pregnancies from groups at risk of this pathology.
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